All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
The Lupus Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Improving outcomes for people of color with chronic plaque psoriasis including scalp involvement
with Paolo Gisondi, Andrew Alexis, and Mona Shahriari
Thursday, February 6, 2025
16:00-17:00 GMT
This independent educational activity is supported by an educational grant from Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. All content is developed independently by the faculty. The funder is allowed no influence on the content.
The Lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lupus Hub cannot guarantee the accuracy of translated content. The Lupus Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Belimumab autoinjector receives U.S. FDA approval for use in pediatric SLE
On May 20, 2024, the U.S. Food and Drug Administration approved the at-home use of belimumab autoinjector, alongside standard therapy, in patients aged ≥5 years with active systemic lupus erythematosus (SLE).1
Previously, patients aged ≥5 years could receive belimumab only through intravenous administration by healthcare professionals in clinical settings. This involved a weight-based dose of 10 mg/kg as a 1-hour infusion, every 4 weeks, post an initial loading phase on Days 0, 14, and 28. Now, if healthcare professionals deem at-home administration suitable, patients’ caregivers can administer belimumab 200 mg autoinjector once weekly to patients weighing ≥40 kg or every other week to patients weighing 15 kg to <40 kg.1
- News release. FDA approves Benlysta (belimumab) autoinjector for children with systemic lupus erythematosus. https://us.gsk.com/en-us/media/press-releases/fda-approves-benlysta-belimumab-autoinjector-for-children-with-systemic-lupus-erythematosus/. Published May 20, 2024. Accessed May 21, 2024.
Related articles
Newsletter
Subscribe to get the best content related to lupus delivered to your inbox